Final patient enrolled in landmark Alzheimers trial-XanADu
Filed with ASX · · 2 pages · English
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- September 2018 Quarterly Update
- Recruitment to close for important Alzheimers trial-XanADu
- R&D Tax Rebate Received Totalling $3.15 Million
- Appendix 4E & Financial Statements
- DSMB reaffirms that XanADu continue without change
Later from Actinogen Medical
- December 2018 Quarterly Update
- 1st participant dosed in important new Xanamem study-XanaHES
- DSMB again reaffirms XanADu trial to continue without change
- New Clinical Development Opportunities for Xanamem
- March 2019 Quarterly Update
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical